無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌原遺伝子の世界市場・臨床パイプラインの見通し

Global Proto Oncogene Market & Clinical Pipeline Insight 2024

発行 KuicK Research 商品コード 603621
出版日 ページ情報 英文 440 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌原遺伝子の世界市場・臨床パイプラインの見通し Global Proto Oncogene Market & Clinical Pipeline Insight 2024
出版日: 2018年02月01日 ページ情報: 英文 440 Pages
概要

当レポートでは、世界の癌原遺伝子の市場を調査し、癌原遺伝子および癌遺伝子製品の概要、癌原遺伝子タンパク質阻害剤のパイプラインの動向、上市済み癌原遺伝子タンパク質阻害剤ののプロファイル、市場成長予測、市場成長への各種影響因子の分析、競合環境、主要企業の分析、将来の展望などをまとめています。

第1章 イントロダクション:癌原遺伝子

  • 概要
  • 伝染性癌遺伝子の発見
  • 癌遺伝子製品

第2章 癌原遺伝子の癌遺伝子への活性化

  • 癌原遺伝子から癌遺伝子へ
    • 遺伝子増幅
    • 染色体転座
    • 突然変異
  • 癌の特徴

第3章 治療標的としての癌遺伝子

  • ERBB2:乳癌の治療標的
  • EGFR:大腸癌の治療標的
  • VEGF:非小細胞肺癌の治療標的
  • PDGFR:腎細胞癌の治療標的

第4章 癌遺伝子の予後・予測における役割

  • HER2
  • BRAF V600E
  • BCL-2
  • SRC

第5章 癌原遺伝子治療薬の市場分析

  • アキシチニブ (Inlyta)
  • ポナチニブ (Iclusig)
  • イマチニブ (Gleevec)
  • スニチニブ (Sutent)
  • パゾパニブ (Votrient)
  • ダブラフェニブ (Tafinlar)
  • バンデタニブ (Caprelsa)
  • ベムラフェニブ (Zelboraf)
  • カボザンチニブ (Cabometyx & Cometriq)
  • ソラフェニブ (Nexavar)

第6章 癌原遺伝子薬剤の市場投入

  • 概要
  • 世界の癌原遺伝子薬剤の売上
  • 世界の癌原遺伝子タンパク質阻害剤のパイプライン:概要

第7章 市場力学

  • 有利な市場指標
  • 商業化における課題

第8章 将来の展望

第9章 癌原遺伝子タンパク質阻害剤のパイプライン:企業・適応症・フェーズ別

  • 研究
  • 前臨床
  • 臨床段階
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 申請済み
  • 承認済み

第10章 上市済み癌原遺伝子タンパク質阻害剤の臨床分析:企業・適応症別

  • アキシチニブ (Inlyta)
  • ポナチニブ (Iclusig)
  • イマチニブ (Gleevec・Glivec・Ruvise)
  • レンバチニブ (Kisplyx・Lenvima)
  • スニチニブ (Sutent)
  • パゾパニブ (Votrient)
  • ダブラフェニブ (Tafinlar)
  • バンデタニブ (Caprelsa, Zactima・Zictifa)
  • ベムラフェニブ (Zelboraf)
  • カボザンチニブ (Cabometyx・Cometriq)
  • ニロチニブ (Tasigna)
  • レゴラフェニブ (Stivarga)
  • ダサチニブ (Sprycel)
  • ソラフェニブ (Nexavar)
  • クリゾチニブ (Xalkori)
  • アパチニブ
  • オマセタキシンメペスクシナート (Synribo)
  • イマチニブ:Pharm-Sintez (Imatib)
  • ファレリアマクロカルパ抽出物 (Phalecarps)

第11章 競合環境

  • ARIAD Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • ChemGenex Pharmaceuticals
  • Dexa Medica
  • エーザイ
  • Exelixis
  • GlaxoSmithKline
  • Novartis
  • Onyx Pharmaceuticals
  • Plexxikon
  • Pfizer
目次

"Global Proto Oncogene Market & Clinical Pipeline Insight 2024" report gives comprehensive insight on ongoing clinical and non-clinical parameters involved in the development of global proto oncogene market in recent years. Currently there are 19 proto oncogene inhibitors drugs commercially available in the market and 166 are in clinical pipeline in various developmental phases.

"Global Proto Oncogene Market & Clinical Pipeline Insight 2024" report highlights:

  • Oncogenes as Therapeutic Targets for Treatment
  • Market Analysis of Proto Oncogene Therapeutic Drugs
  • Dosage & Price Analysis of Drugs
  • Patent & Approval Year Insight
  • Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Marketed Proto Oncogene Inhibitors Clinical Insight by Company & Indication

Cancer has been designated as a complex genetic and cellular disease as it affects growth of cells due to sudden alterations in the genes. However, most of the conventional anti-cancer therapies developed for treating cancer were directed towards killing the tumor cells and were ineffective in inhibiting the cancer-causing transformations that occur in genes of normal cells. Nevertheless several modern cancer therapies have been recently developed including targeted drugs and immunotherapeutics. Although these regimens interrupt the expression of cancer genes but either by affecting the gene indirectly or with lesser efficacy which further leads to ineffective treatment of cancer.

Proto-oncogene Inhibitors are recently developed class of anti-cancer therapeutics possessing a unique mode of action as they directly inhibit the activation of cancer causing genes. Proto-oncogenes are inactivated form of cancerous genes which function normally until they're activated by several factors or cellular mechanisms. When such factors activate proto-oncogene, then it gets transformed to form an oncogene which induces cancer development. Proto-oncogene Inhibitors are involved in direct inhibition of this transformation from inactive proto-oncogene to active oncogene and restricting cancer growth.

Global Cancer Therapy Market has been flourished with a wide range of proto-oncogene inhibitors in the past decade and has acquired a larger portion of the market. Furthermore, presence of a wide variety of proto-oncogenes in a human body has provided several targets for developing unique proto-oncogene inhibitors. These facts clearly indicate that proto-oncogene inhibitors is a major class of anti-cancer therapeutics comprising a wide variety of inhibitors based on different proteins and mechanisms which are affected by particular oncogenes.

Proto-oncogene Inhibitors represent a well-established global market as it possess close to 20 commercialized products amongst which more than 5 are in the list of top selling anti-cancer drugs. For instance, Imatinib is one of the proto-oncogene inhibitors which have collected more than US$ 10 Billion in past four to five years. Additionally, another proto-oncogene inhibitor namely Sutent has generated US$ 2 Billion in past three years.

Moreover more than 20 drugs are in the later phases of clinical pipeline and are expected to be approved in the coming four to five years. Furthermore, Biosimilars of highly popular proto-oncogene inhibitors have already been commercialized and have gained an excellent response in the market. Patent expiration of other popular proto-oncogene inhibitors will provide opportunities for the development and commercialization of more biosimilars.

Nonetheless, as proto-oncogene inhibitors are a larger class of anti-cancer therapeutics, development and advancement in genomic studies have successfully led to identification of more targets to form proto-oncogene inhibitors. Due to this reason, proto-oncogene inhibitors market is expected to expand with the entrance of more sub-classes of drugs under this class. This indicates that although proto-oncogene inhibitor market is well-established yet highly opportunistic for the scientific community as well as the pharmaceutical market.

Initially approved products in the proto-oncogene inhibitor market such as Imatinib has stayed in the market since 2001 and has continuously generated high revenues; even in the presence of highly competitive market with successive approvals of new proto-oncogene Inhibitors. Such examples are appropriate examples suggest that Global proto-oncogene market will continue to grow exponentially even in a highly competitive market space.

Proto-oncogene inhibitors are actively being supported by large scale as well as small scale pharmaceutical companies from different regions of the world. Key market players are Dexa Medica, Eisai Pharmaceuticals, Exelixis, Pfizer, Novartis, AstraZeneca and many more. Additionally, investments and funding from private as well as public sector is further an encouraging factor for the research laboratories and science institutes to develop unique proto-oncogene inhibitors indicating that this market is expected to grow at an unusually high growth rate in the coming future.

Table of Contents

1. Introduction to Proto Oncogenes

  • 1.1 Overview
  • 1.2 Discovery of Transmissible Cancer Gene
  • 1.3 Products of Oncogenes

2. Activation of Proto Oncogene to Oncogenes

  • 2.1 From Proto Oncogenes to Oncogenes
    • 2.1.1 Gene Amplification
    • 2.1.2 Chromosomal Translocation
    • 2.1.3 Mutations
  • 2.2 Hallmarks of Cancer

3. Oncogenes as Therapeutic Targets for Treatment

  • 3.1 ERBB2 as a Target for Breast Cancer Therapy
  • 3.2 EGFR as a Target for Colorectal Cancer Therapy
  • 3.3 VEGF as a Target for Non-Small Cell Lung Cancer
  • 3.4 PDGFR as a Target for Renal Cell Carcinoma

4. Prognostic & Predictive Role of Oncogenes

  • 4.1 HER2
  • 4.2 BRAF V600E
  • 4.3 BCL-2
  • 4.4 SRC

5. Market Analysis of Proto Oncogene Therapeutic Drugs

  • 5.1 Axitinib (Inlyta)
  • 5.2 Ponatinib (Iclusig)
  • 5.3 Imatinib (Gleevec)
  • 5.4 Sunitinib (Sutent)
  • 5.5 Pazopanib (Votrient)
  • 5.6 Dabrafenib (Tafinlar)
  • 5.7 Vandetanib (Caprelsa)
  • 5.8 Vemurafenib (Zelboraf)
  • 5.9 Cabozantinib (Cabometyx & Cometriq)
  • 5.10 Sorafenib (Nexavar)

6. Market Introduction of Proto Oncogenes

  • 6.1 Overview
  • 6.2 Global Sales of Proto-Oncogene Drugs
  • 6.3 Global Proto Oncogene Protein Inhibitors Pipeline Overview

7. Global Proto Oncogene Market Dynamics

  • 7.1 Favorable Market Parameters
  • 7.2 Commercialization Challenges

8. Future Perspective of Proto Oncogene Market

9. Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Clinical
  • 9.4 Phase-I
  • 9.5 Phase-I/II
  • 9.6 Phase-II
  • 9.7 Phase-III
  • 9.8 Preregistration
  • 9.9 Registered

10. Marketed Global Proto-Oncogene Protein Inhibitors Clinical Insight by Company & Indication

  • 10.1 Axitinib (Inlyta)
  • 10.2 Ponatinib (Iclusig)
  • 10.3 Imatinib (Gleevec, Glivec & Ruvise)
  • 10.4 Lenvatinib (Kisplyx & Lenvima)
  • 10.5 Sunitinib (Sutent)
  • 10.6 Pazopanib (Votrient)
  • 10.7 Dabrafenib (Tafinlar)
  • 10.8 Vandetanib (Caprelsa, Zactima & Zictifa)
  • 10.9 Vemurafenib (Zelboraf)
  • 10.10 Cabozantinib (Cabometyx & Cometriq)
  • 10.11 Nilotinib (Tasigna)
  • 10.12 Regorafenib (Stivarga)
  • 10.13 Dasatinib (Sprycel)
  • 10.14 Sorafenib (Nexavar)
  • 10.15 Crizotinib (Xalkori)
  • 10.16 Apatinib
  • 10.17 Omacetaxine Mepesuccinate (Synribo)
  • 10.18 Imatinib - Pharm-Sintez (Imatib)
  • 10.19 Phaleria Macrocarpa extract (Phalecarps)

11. Competitive Landscape

  • 11.1 ARIAD Pharmaceuticals
  • 11.2 AstraZeneca
  • 11.3 Bayer Healthcare
  • 11.4 Bristol-Myers Squibb
  • 11.5 ChemGenex Pharmaceuticals
  • 11.6 Dexa Medica
  • 11.7 Eisai Pharmaceuticals
  • 11.8 Exelixis
  • 11.9 GlaxoSmithKline
  • 11.10 Novartis
  • 11.11 Onyx Pharmaceuticals
  • 11.12 Plexxikon
  • 11.13 Pfizer

List of Figures

  • Figure 1-1: Historical Development of Oncogenes in Various Cancer Cell Lines
  • Figure 1-2: Organization of the Proto Oncogene Products
  • Figure 2-1: Activation Methods of Oncogenes from Proto Oncogenes
  • Figure 2-2: Gene Amplification Step in the Conversion of Proto Oncogenes to Oncogenes
  • Figure 2-3: Chromosomal Translocation for the Activation Oncogene from Proto Oncogene
  • Figure 2-4: Classification of the Hallmarks of Cancer
  • Figure 3-1: Role of VEGF as a Target to Non-Small Cell Lung Cancer
  • Figure 3-2: PDGFR Target for the Treatment of Renal Cell Carcinoma
  • Figure 5-1: Axitinib- Patent Approval & Expiration Year in US
  • Figure 5-2: Axitinib- Patent Approval & Expiration Year in Europe
  • Figure 5-3: Axitinib Dosage Analysis (mg/Day)
  • Figure 5-4: Available Concentrations of Axitinib Oral Tablet (mg)
  • Figure 5-5: Inlyta- Price Analysis by Concentration (US$/Unit), 2018
  • Figure 5-6: Axitinib Price Analysis US$/Packet), 2018
  • Figure 5-7: Axitinib Treatment Cost (US$/Cycle), 2017
  • Figure 5-8: Ponatinib- Patent Approval Year & Expiration Year in US
  • Figure 5-9: Ponatinib- Patent Approval Year & Expiration Year in Europe
  • Figure 5-10: Iclusig Dosage Analysis (mg/Day)
  • Figure 5-11: Available Concentrations of Iclusig Oral Tablet Drug, mg
  • Figure 5-12: Iclusig- Price Analysis (US$), 2017
  • Figure 5-13: Imatinib- Patent Approval Year & Patent Expiration Year in US
  • Figure 5-14: Imatinib- Patent Approval Year & Patent Expiration Year in Europe
  • Figure 5-15: Imatinib Price Analysis by Concentration (US$/Unit), 2017
  • Figure 5-16: Imatinib Price Analysis by Concentration (US$/Packet), 2017
  • Figure 5-17: Sunitinib- Patent Approval Year & Expiration Year in US
  • Figure 5-18: Sunitinib- Patent Approval Year & Expiration Year in Europe
  • Figure 5-19: Available Concentrations of Sunitinib Drug, mg
  • Figure 5-20: Sutent Capsule Price by Concentration (US$/Unit), 2017
  • Figure 5-21: Sunitinib- Price Analysis by Concentration (US$/Packet), 2017
  • Figure 5-22: Pazopanib- Patent Approval Year & Patent Expiration Year in US
  • Figure 5-23: Pazopanib- Patent Approval Year & Patent Expiration Year in Europe
  • Figure 5-24: Pazopanib Dosage Analysis (mg/Day)
  • Figure 5-25: Pazopanib Price Analysis by Quantity (US$), 2017
  • Figure 5-26: Dabrafenib- Patent Approval & Expiration Year in US
  • Figure 5-27: Dabrafenib- Patent Approval & Expiration Year in Europe
  • Figure 5-28: Dabrafenib Dosage Analysis (mg/Day)
  • Figure 5-29: Available Concentration of Dabrafenib Drug, mg
  • Figure 5-30: Dabrafenib Price Analysis by Concentration (US$/Unit), 2017
  • Figure 5-31: Tafinlar Capsule Average Price Analysis by Concentration (US$/120 Capsules), 2017
  • Figure 5-32: Vandetanib- Patent Approval & Expiration Year in US
  • Figure 5-33: Vandetanib- Patent Approval & Expiration Year in Europe
  • Figure 5-34: Vandetanib Dosage Analysis (mg/Day)
  • Figure 5-35: Available Concentrations of Vandetanib Drug, mg
  • Figure 5-36: Vandetanib Price Analysis (US$/Unit), 2017
  • Figure 5-37: Vandetanib- Drug Cost (US$) in Concentration of 100 mg & 300 mg for 30 Tablets, 2017
  • Figure 5-38: Vemurafenib- Patent Approval Year & Expiration Year in US & Europe
  • Figure 5-39: Vemurafenib- Patent Approval Year & Expiration Year in Europe
  • Figure 5-40: Vemurafenib Dosage Analysis (mg/Day)
  • Figure 5-41: Vemurafenib- Market Cost of Drug (US$) for 112 Tablets & Per Unit Cost, 2017
  • Figure 5-42: Cabozantinib- Patent Approval Year & Expiration Year in US
  • Figure 5-43: Cabozantinib- Patent Approval Year & Expiration Year in Europe
  • Figure 5-44: Cabozantinib Dosage Analysis (mg/Day)
  • Figure 5-45: Available Concentrations of Cabozantinib Oral Tablet, mg
  • Figure 5-46: Available Drug Concentrations of Cometriq Oral Capsule, mg
  • Figure 5-47: Cabozantinib- Drug Cost of 20mg Concentration (US$) for 30 Tablets & Per Unit Dose, 2017
  • Figure 5-48: Cost of Cometriq Capsules for the Supply of 50 Capsules of Different Concentrations, (US$)
  • Figure 5-49: Sorafenib- Patent Approval Year & Expiration Year in US
  • Figure 5-50: Sorafenib- Patent Approval Year & Expiration Year in Europe
  • Figure 5-51: Sorafenib- Drug Cost for 120 Tablets & Per Unit Dose (US$), 2017
  • Figure 6-1: Global- Axitinib Drug Sales (US$ Million), 2015 & 2016
  • Figure 6-2: Iclusig - Sales (US$ Million), 2015
  • Figure 6-3: Iclusig - Sales (US$), 2016 & 2017
  • Figure 6-4: Global- Sales Revenue of Sunitinib Drug (US$ Billion), 2015 & 2016
  • Figure 6-5: Global- Sales of Pazopanib Drug (US$ Million), 2015 & 2016
  • Figure 6-6: Global- Sales Revenue of Vemurafenib Drug (US$ Million), 2015 & 2016
  • Figure 6-7: Global- Sales of Imatinib (US$ Billion), 2014-2017
  • Figure 6-8: Global Sales of Dabrafenib Drug (US$ Million), 2015 & 2016
  • Figure 6-9: Global Sales Revenue of Sorafenib Drug (US$ Million), 2014-2016
  • Figure 6-10: Cabozantinib (Cabometyx & Cometriq) - Sales (US$ Million), 2016 & 2017*
  • Figure 6-11: Cabometyx & Cometriq - Sales (US$ Million), 2016 & 2017*
  • Figure 6-12: Global Proto Oncogene Protein Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
  • Figure 6-13: Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
  • Figure 7-1: Favorable Factors which Promote the Market Growth of Proto Oncogenes
  • Figure 7-2: Challenges to the Market Growth of Proto Oncogenes
  • Figure 8-1: Frontiers for the Inhibition of Cancer Development by Active Oncogenes

List of Tables

  • Table 3-1: Possible Ways to Overcome ErBb2 Mediated Chemoresistance
  • Table 3-2: Components of EGFR Signaling Pathway Important in Colorectal Cancer
  • Table 4-1: Role of Cancer Oncogene as Predictive & Prognostic Biomarker
  • Table 5-1: Imatinib Dosage for Various Indications (mg/Day & mg/m2/Day)
  • Table 5-2: Cost Effective Analysis of Imatinib Drug
  • Table 5-3: Clinical Efficacy Results of Sunitinib Drug in Cancer Treatment
  • Table 5-4: Clinical Efficacy Results of Pazopanib Drug in Cancer Treatment
  • Table 5-5: Clinical Effective Analysis of Dabrafenib Drug
  • Table 5-6: Clinical Effective Analysis of Vandetanib Drug
  • Table 5-7: Clinical Efficacy of Vemurafenib Drug in Cancer Treatment
Back to Top